By Mark Maietta, President, YPrime
The goal of modern drug development is to remove the burdens and barriers inherent to clinical trial participation. The pace of innovation in digital technology and growing interest in decentralized clinical trial (DCT) models has accelerated home-based participation and/or a reduction in clinic visits and has had transformative effects on the design and execution of oncology clinical trials.
Given the requirements of drug administration for specific drugs in oncology clinical trial protocols (i.e., infusion, radiation, etc.), completely virtual trials are not likely soon, but a DCT model may include advanced telemedicine, home health visits, and/or visits to local labs, and may incorporate key technology-based elements to reduce the need for frequent site visits and provide more convenience for the patient and caregiver. Electronic clinical outcome assessments (eCOA) and emerging connected technologies are effectively bridging the gap between traditional models and the future of oncology drug development that promises more choice, flexibility, and convenience for patients.
To learn more about YPrime, visit their Clinical Leader page.